Viridian Therapeutics
VRDN
59 hedge funds and large institutions have $62.7M invested in Viridian Therapeutics in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 7 closing their positions.
243% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 7
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
16% more funds holding
Funds holding: 51 → 59 (+8)
4% more capital invested
Capital invested by funds: $60M → $62.7M (+$2.66M)
0.26% more ownership
Funds ownership: 1.72% → 1.98% (+0.26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.75M |
| 2 |
6CM
683 Capital Management
New York
|
+$3.62M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.96M |
| 4 |
AG
Artal Group
Luxembourg
|
+$2.9M |
| 5 |
BlackRock
New York
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$541K |
| 2 |
Renaissance Technologies
New York
|
-$371K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$321K |
| 4 |
VCA
Verdence Capital Advisors
Hunt Valley,
Maryland
|
-$294K |
| 5 |
BWP
BSW Wealth Partners
Boulder,
Colorado
|
-$232K |
VRDN Hedge Fund Activity: Q1 2018 in Review
59 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2018, worth a combined $62.7M — up 4.4% from $60M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VRDN positions and 7 closed out — a net gain of 9 holders — while 24 added to existing stakes and 7 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.75M. The largest seller was Virtu Financial, exiting entirely with an estimated $541K sold.
- 59 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2018, up from 51 in Q4 2017.
- Funds reported $62.7M of Viridian Therapeutics stock for Q1 2018, up 4.4% quarter-over-quarter.
- 16 funds opened new Viridian Therapeutics positions in Q1 2018 and 7 closed out, a net change of +9 holders.
- The largest Viridian Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $8.75M added.
- The largest Viridian Therapeutics seller in Q1 2018 was Virtu Financial, an estimated $541K sold.
Based on aggregated 13F filings for Q1 2018.